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Abstract
Gastric cancer is one of the most aggressive malignancies, with limited treatment options in both locally advanced and meta-
static setting, resulting in poor prognosis. Based on genomic characterization, stomach tumour has recently been described as 
a heterogeneous disease composed by different subtypes, each of them with peculiar molecular aspects and specific clinical 
behaviour. With an incidence of 22% among all western gastric tumour cases, stomach cancer with microsatellite instability 
was identified as one of these subgroups. Retrospective studies and limited prospective trials reported differences between 
gastric cancers with microsatellite stability and those with instability, mainly concerning clinical and pathological features, 
but also in regard to immunological microenvironment, correlation with prognostic value, and responses to treatment. In 
particular, gastric cancer with microsatellite instability constitutes a small but relevant subgroup associated with older age, 
female sex, distal stomach location, and lower number of lymph-node metastases. Emerging data attribute to microsatellite 
instability status a favourable prognostic meaning, whereas the poor outcomes reported after perioperative chemotherapy 
administration suggest a detrimental role of cytotoxic drugs in this gastric cancer subgroup. The strong immunogenicity 
and the widespread expression of immune-checkpoint ligands make microsatellite instability subtype more vulnerable to 
immunotherapeutic approach, e.g., with anti-PD-L1 and anti-CTLA4 antibodies. Since gastric cancer with microsatellite 
instability shows specific features and clinical behaviour not overlapping with microsatellite stable disease, microsatellite 
instability test might be suitable for inclusion in a diagnostic setting for all tumour stages to guarantee the most targeted and 
effective treatment to every patient.
Keywords Microsatellite instability · Gastric cancer · Molecular stratification · Predictive and prognostic value · Adjuvant 
chemotherapy · Immune-checkpoint inhibitors
Introduction
Gastric cancer (GC) is one of the most common tumours and 
the third leading cause of cancer-related death worldwide 
[1]. The addition of targeted drugs to the established chemo-
therapeutic scenario of treatment has determined a modest 
improvement in overall survival, but, unfortunately, the prog-
nosis remains poor [2–4]. Emerging data suggest that patients’ 
outcomes do not only depend on staging but also on specific 
molecular and histopathologic tumour features [5, 6]. Indeed, 
two detailed genomic characterizations of gastric cancer 
have recently been developed by The Cancer Genome Atlas 
(TCGA) and the Asian Cancer Research Group (ACRG) [5, 
6], proving that GC is a complex and heterogeneous disease. 
According to TCGA genomic characterizations, GC can be 
divided into four subgroups (Table 1): (1) tumours positive for 
Epstein–Barr Virus (EBV) infection; (2) microsatellite insta-
bility-high tumours (MSI-H); (3) genomically stable tumours 
(GS); (4) tumours with chromosomal instability (CIN) [5, 6]. 
Interestingly, the MSI-H subgroup was identified as a sepa-
rate entity of GC in both of these classifications [5, 6], with a 
reported incidence in the western population of 22% [5]. The 
frequency of MSI across gastrointestinal cancers and tumours 
of other districts with high prevalence of MSI (> 10%) are 
summarized in Table 2. Microsatellites are short and repetitive 
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DNA sequences randomly widespread throughout the genome 
[5, 7, 8]. The mismatch repair system deficiency (MMRD) is 
generally caused by germline mutations or sporadic epigenetic 
silencing that lead to insertion or deletions of nucleotides in 
the microsatellite regions during DNA replication; these phe-
nomena are known as microsatellite instability (MSI) [9–11]. 
Although the role of MSI-H in colorectal cancer as a predictive 
and prognostic factor is well established [12–16], the correla-
tion between MSI, and clinical and pathological features in GC 
remains ambiguous, with a few available data from prospective 
trials [17–20]. Interestingly, recent studies have hypothesized 
that alterations in the mismatch repair (MMR) system may 
predict clinical benefit for treatment with immune-checkpoint 
inhibitors, due to a positive correlation between MSI-H and 
PD-L1 expression, as shown in Fig. 1 [21–24]. In this review, 
the current evidences about microsatellite instability-high 
(MSI-H) gastric cancer (GC) are summarized, with a special 
focus on pathological characteristics, predictive and prognostic 
Table 1  Four gastric cancer 
subtypes, as described by 
TCGA, with reported frequency 
and main histological and 
molecular features
TCGA gastric cancer subgroups Frequency (%) Main characteristics
Epstein–Barr virus (EBV) 9 Gastric fundus location
CDKN2A silencing
Hypermethylation of CpG islands
Over-expression of immune-checkpoint ligands
Microsatellite instability (MSI) 22 Body and pyloric gastric location
Correlation with Lauren intestinal subtype
Hypermutation status
MLH1 silencing and hypermethylation of CpG islands
Genomically stable (GS) 20 Homogenous distribution to all portions of the stomach
Correlation with Lauren diffuse histology
CDH1 and RHO mutations, CLDN18–ARHGAP fusion
Chromosomal instability (CIN) 49 Homogenous distribution to all portions of the stomach
Correlation with Lauren intestinal histology
Activation of RAS pathway
Mutation of TP53
Table 2  Percentage of MSI frequency in gastrointestinal and non-gastrointestinal cancers with high prevalence (≥ 10%) of MSI status
Tumour site MSI frequency 
(%)
Study
Colorectal cancer 15 Poynter et al. [68] MSI frequency across gastrointestinal tumours
Hepatocellular carcinoma 10–43 Karachristos et al. [69]
Chiappini et al. [70]
Gastric cancer 10–22 Kim et al. [44]
The Cancer Genome Atlas 
Network [5]
Intrahepatic cholangiocarcinoma 10 Silva et al. [71]
Duodenal and ampullary carcinoma 10 Achille et al. [72]
Ruemmele et al. [73]
Agaram et al. [74]
Achille et al. [75]
Esophageal adenocarcinoma 7 Farris et al. [76]
Gallbladder cancer 0–42 Silva et al. [71]
Yoshida et al. [77]
Pancreatic adenocarcinoma (ductal) 0–13 Yamamoto et al. [78]
Laghi et al. [79]
Endometrial cancer 22–33 Zighelboim et al. [80]
Aguirre et al. [81]
Non-gastrointestinal tumours with higher MSI 
frequency (≥ 10%)
Sebaceous skin cancer 20–25 Cesinaro et al. [82]
Kruse et al. [83]
Ovarian cancer 10 Jensen et al. [84]
Segev et al. [85]
Thyroid cancer 0–63 Stoler et al. [86]
Bauer et al. [87]
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Fig. 1  Different immune microenvironment in microsatellite insta-
bility-high (MSI) hypermutated tumours and in microsatellite stable 
(MSS) tumours with low-mutational rate. a In the presence of defi-
cient mismatch repair (MMR), DNA replications errors go undetected 
and unrepaired, leading to a tumour with high mutational burden. 
Hyper-mutated cancer cells produce several neo-antigens, which 
stimulate T-cell activation and tumour infiltration by immune cells. 
To counteract this vigorous immune response, tumour cell exposes 
checkpoint molecules, e.g., PD-L1, to inhibit anti-tumour activity. b 
In the presence of functional MMR system, replication errors occur 
rarely with lower mutational rate and, as a consequence, limited pro-
duction of neo-antigens. For this reason, in MSS tumour, the amount 
of T-cell infiltration and checkpoint molecules exhibition is low. The 
peculiar immune microenvironment of MSI tumours is thought to 
explain why they are ideal target for therapy with immune-checkpoint 
inhibitors. MHC major histocompatibility complex, TCR T-cell recep-
tor
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values, and future perspectives for clinical approaches of 
MSI-H GC subgroup.
Microsatellite instability and the mismatch 
repair genes system
Microsatellites are DNA sequences with a length ranging 
from one to six repetitions of nucleotides (usually between 
10 and 60 times) [25]. These DNA motifs are scattered 
throughout coding and non-coding regions of the genome, 
highly polymorphic among population but stable in each 
individual [25]. The MMR system consists of several 
proteins, which include the products of hMLH1, hMSH2, 
hMSH6, and hPMS2 genes, which are responsible for sur-
veillance of correct DNA replication. The MMR system 
targets and corrects replication errors (e.g., base mismatch, 
insertions, and deletions) when detected [26–28]. The het-
erodimeric protein complexes hMSH2/hMSH6 and hMSH2/
hMSH3 are responsible for the initial detection of replication 
errors. The subsequent recruitment of the complex formed 
by hMLH1 and hPMS2 removes the mismatched nucleo-
tide or fragment and allows DNA re-synthesis [28]. Inac-
tivation of MMR proteins can be caused by mutations in 
the coding region, promoter methylation, or chromosomic 
rearrangements that lead to loss of heterozygosity [28–30]. 
Microsatellite unstable GC can be observed in sporadic GC 
and in the setting of Lynch syndrome [11, 29, 30]. Lynch 
syndrome is caused by autosomal dominant mutations in 
the MMR genes—mainly hMLH1 and hMSH2 and less fre-
quently hPMS2 and hMSH6 [30]. Moreover, a constitutional 
3′-end deletion of EPCAM, which is immediately upstream 
of the MSH2 gene, may cause Lynch syndrome through epi-
genetic silencing of MSH2 [31]. Patients affected by Lynch 
syndrome present an increased predisposition to develop 
colorectal cancer and endometrial cancer, but also to ovar-
ian and gastric cancer occurring at a younger age (11.3-fold 
in the 30s and 5.5-fold in the 40s) [28–30]. Increased risk for 
developing pancreatic, bladder and breast cancer, and most 
possibly also prostate cancer has been related with Lynch 
syndrome carriers [31]. Patients with MSH6 mutations 
appear to be particularly at risk of gastrointestinal and endo-
metrial cancers, whereas carriers of an MSH2 gene mutation 
have the highest cancer risks across the spectrum, especially 
for the development of urinary tract cancer [31]. In the spo-
radic setting, more than 50% of MSI GCs contain an epige-
netic hypermethylation of hMLH1 promoter, whereas muta-
tions in hMLH1 and hMSH2 have been reported in 12–15% 
of this GC subgroup [32]. Gene expression inactivation by 
alternative unknown genetic or epigenetic alterations have 
been hypothesized to be responsible for all of the remain-
ing cases of microsatellite unstable GC [32]. The functional 
loss of MMR proteins results in a highly mutated phenotype 
with a large number of frameshift and missense mutations 
in key oncogenes and tumour suppressor genes. Mutations 
in genes responsible for cell cycle regulation and apoptosis 
(e.g., TGFβ RII, IGFIIR, TCF4, RIZ, BAX, CASPASE5, FAS, 
BCL10, and APAF1) or for genomic integrity maintenance 
(e.g., hMSH6, hMSH3, MED1, RAD50, BLM, ATR , and 
MRE11) have been also associated with MSI-H GC [11]. 
Moreover, increased expression of mitotic pathways compo-
nents, such as AURKA A/B, E2F, FOXM1, PLK1, and tar-
gets of MYC activation, has been described and confirmed 
on a transcriptomic level in MSI-H tumours [5]. Indeed, 
inactivation of MMR genes is not, by itself, a transforming 
event and additional genetic changes are needed to determine 
tumour progression. It is well established that MSI cancers 
are associated with 100- to 1000-fold increased mutation 
rates compared to microsatellite stable (MSS) tumours [11, 
29, 30, 33]. The repetitive sequences of microsatellites are 
particularly prone to replication errors, and therefore, they 
can be used as a marker for an intact or defective MMR 
system [11].
Diagnosis of MSI
The increasing knowledge about the prognostic and predic-
tive role of MSI-H vs MSS in several cancer subtypes has 
led to a larger number of patients routinely tested for this 
molecular feature [32]. Gastrointestinal and non-gastroin-
testinal cancers with high prevalence of MSI-H (≥ 10%) are 
summarized in Table 2. For an accurate determination of 
MSI status and the subsequent therapeutic decision, sen-
sitive, fast, and precise techniques are necessary [30–32]. 
Currently, several different methods are validated and in use 
to detect an MMR deficient cancer:
1. polymerase chain reaction (PCR) amplification of micro-
satellite sequences;
2. immunohistochemistry (IHC) staining for expression of 
MMR proteins;
3. next-generation sequencing (NGS) for detection of MSI.
MSI evaluation by polymerase chain reaction (PCR)
PCR amplification with specific primers for microsatel-
lite repeats results in a distinctive amplification profile [30, 
34]. By comparing the allelic position of the microsatellite 
locus in tumour and normal tissue, MSI can be assessed 
as “shift” in the pherogram of one or more microsatellites 
as illustrated in Fig. 2. To reach high specificity and sensi-
tivity and also to ensure reproducibility and standardiza-
tion between different laboratories, The National Cancer 
Institute recommends the so-called Bethesda Panel as ref-
erence for diagnostic testing [7]. This panel is composed 
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of five microsatellite markers specific for two mononucleo-
tide loci (BAT-25 and BAT-26) and three dinucleotide loci 
(D2S123, D5S346, and D17S250) [7, 29]. These regions 
are amplified in parallel using fluorescent PCR and their 
sizes are evaluated by subsequent capillary electrophoresis 
[34]. Using this method, three different stati can be estab-
lished based on different allelic size patterns in the cancer 
tissue compared to the normal one. The MSI-high (MSI-H) 
status is given by a shift in size in at least two of the five 
microsatellite loci; MSI-low (MSI-L) is given by a shift in 
size in one locus out of five and microsatellite stable (MSS) 
with any shift in cancer tissue compared to the normal one 
[7, 30, 34]. The dinucleotide markers were demonstrated 
to be less sensitive and specific than mononucleotide for 
the detection of tumours with mismatch repair deficiencies 
[35]. Furthermore, mononucleotide markers are more com-
monly quasi-monomorphic, potentially obviating the need 
to test the corresponding normal DNA. [7]. To overcome 
the limitations of Bethesda system due to the presence of 
dinucleotide markers, a commercial available panel has 
recently been developed by Promega Corporation. This is 
commonly employed in the diagnostic practice and replaced 
dinucleotides of the Bethesda Panel with mononucleotide 
markers (NR-21, NR-24, and MONO-27, see Fig. 2) helping 
to resolve cases of MSI-low into either MSI-H or MSS by 
comparison of tumour and the surrounding normal tissue as 
illustrated in Fig. 2 [7, 35].
MSI evaluation by immunohistochemistry (IHC)
Immunohistochemistry staining allows detection of 
expression or total absence of MMR proteins and relative 
scoring is possible. This method shows comparable perfor-
mance characteristics and high concordance rate (> 90%) 
with MSI detection with PCR [8]. The loss of expression 
of a single protein or of a heterodimeric couple of the 
MMR complex suggests the presence of MMRD; thus, it 
is an indirect evidence of MSI. On protein level, hMLH1 
Fig. 2  Representative capillary 
electrophoresis (pherogram) 
of the Promega MSI Analysis 
System generated using Gen-
eMapper 3.7 Analysis Software. 
The upper part of the figure 
shows microsatellite stability 
(MSS) in normal tissue, without 
shifted alleles. The lower part 
is representative of tumour 
microsatellite instability-high 
(MSI) in all loci, with evident 
alleles shifting. Green: peaks 
of mononucleotides NR-21, 
BAT-25, and MONO-27. Blue: 
peak of BAT-26. Black: peak 
of NR-24
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and hMSH2 are stable without their respective dimeric 
partners’ hPMS2 and hMSH6, whereas these latter compo-
nents are rarely stable without their counterparts [17, 28, 
30]. Therefore, tumours with mutated hMLH1 or hMSH2 
genes usually show loss of the respective functional dimer; 
conversely, mutations of hPMS2 or hMSH6 genes gen-
erate loss of only the affected protein [28, 30]. Hence, 
IHC allows the determination which of the MMR genes is 
defective and supports the decision about further genetic 
analysis [30, 34]. It must be taken into account that IHC 
provides misleading information for those rare cases of 
missense mutations in hMLH1 or hMSH6 genes, resulting 
in translated proteins with normally antibody affinity but 
missing enzymatic activity. In these cases, only PCR-based 
MSI testing can help to determine whether there are true 
functional MMR proteins through these mutations [7, 11].
Comparison between MSI testing via PCR and IHC
Many studies have attempted to evaluate and compare the 
best and cost-effective method in defining the MMR status 
between IHC and PCR [7, 8, 36]. Moreover, it has been 
evidenced in many reports the high correlation between 
IHC results and PCR-based tests in determining the phe-
notypic trait of the tumour [7, 36]. In a recent study, a 
discrepancy between MMRD and MSI assessment was 
found [20]. Nevertheless, the overall concordance between 
immunohistochemical analysis of MMR protein expres-
sion and MSI was high [20]. The authors explained the 
imperfect correlation with interobserver variability in 
immunohistochemical analysis assessment, heterogeneity 
of biomarker expression in gastric cancer, and the pres-
ence of normally translated but non-functional MMR pro-
teins in the setting of a missense MLH1 mutation, or rare 
genomic defects that result in MSI-H status with intact 
MMRD function, e.g., polymerase DNA ε1 mutation [20].
One of the advantages of IHC technique consists in 
its wide integration in routine testing in molecular and 
diagnostic pathology laboratories and in its ability in 
identifying which gene should be investigated for further 
molecular analyses in case of suspected hereditary cancer 
syndromes [30, 36]. Moreover, when IHC is used only 
the tumour tissue is required, whereas both normal and 
tumour samples are required for MSI testing with PCR 
[7]. Molecular testing with PCR detects MSI directly as a 
consequence of MMRD. In these 5–11% of MSI malignan-
cies that do not exhibit MMR protein loss, usually due to 
retained antigenicity in an otherwise non-functional pro-
tein, IHC may underestimate MSI-H cases. In this situa-
tion, PCR-based test helps defining the correct diagnosis 
[20, 34, 36].
MSI evaluation by next‑generation sequencing 
(NGS)
Some laboratories started to use NGS to diagnose the micro-
satellite status [37–39]. In most cases, also NGS-based MSI 
determination needs paired tumour and normal tissue [38, 
39]. Recently, a MSI assay that uses data from a commercial 
available NGS panel for determination of the MSI status has 
been established [37]. One advantage of this NGS-based 
assay for MSI evaluation is that it does not require matched 
samples from normal tissue. Furthermore, NGS-based meth-
ods cover a broader range of microsatellite loci; thus, it is not 
limited to the five microsatellite sites used in the PCR-based 
method [37]. The disadvantages are the high investment 
costs per sample for NGS and the longer time needed to 
perform NGS run and bioinformatic analysis in comparison 
to PCR and IHC-based MSI analysis methods.
Clinico‑pathological features of MSI gastric 
cancer
The highest incidence of GC is reported amongst Asiatic 
population [1], and thus, it is not unexpected that most of 
the information about histologic and clinical characteris-
tics of microsatellite unstable GC is based on retrospective 
studies involving Asian GC patients [40–43]. Furthermore, 
MSI-H GC prevalence in Asians is commonly < 10% of all 
GC cases [44], lower than most of the rates reported in the 
Western studies concerning this topic [5, 45, 46]. Many data 
have been collected and analyzed to clarify whether MSI-H 
could be considered as a separate GC subgroup with specific 
histopathologic features, clinical behaviour, and different 
response to chemotherapy and immunotherapy. TCGA first 
provided a comprehensive molecular characterization of GC 
based on 295 cases from a western population, and catego-
rized them into four different subtypes (Table 1) [5]. The GC 
MSI-H subgroup is characterized by elevated mutation rate 
in genes encoding proteins involved in oncogenic signalling 
pathways, mutations at “hotspot” regions such as PIK3CA, 
ERBB3, ERBB2, and EGFR genes already described in other 
malignancies, e.g., colon and breast cancers, as well by 
methylation at the hMLH1 gene promoter [5, 47, 48]. Inter-
estingly, in microsatellite unstable GC, BRAF V600E muta-
tion, frequently reported in sporadic colon cancer caused by 
MSI, has never been described [47]. In general, MSI-H GC 
is associated to older age (> 65-year-old patients), female 
sex, onset in the distal stomach, intestinal type (according 
to Lauren classification) and more common in patients with 
multiple synchronous gastric cancers than in those with a 
solitary tumour [49]. The examination of multiple early GC 
treated with endoscopic mucosal resection revealed that 
MSI-H status increased the frequency of both synchronous 
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and metachronous GC [50]. Among all these features, the 
association between onset at older age and MSI-H phenotype 
is observed in most of the studies focusing on this topic [40, 
42, 44–46]. Methylation of hMLH1 gene and its progressive 
loss of expression have been related to aging [51]. Methyla-
tion of this gene is the main cause for microsatellite unstable 
status in sporadic GC; this might explain the connection 
between onset of MSI-H GC and aging [29, 30]. Interest-
ingly, in many studies, this subgroup showed a specific 
phenotype sharing similarities with medullary-type cancer 
or presenting lympho-plasmacytoid appearance [46]. More 
precisely, it was observed that MSI-H GC was enriched with 
highly pleomorphic tumour cells arranged in several growth 
patterns surrounded by an inflammatory stroma, with push-
ing tumour borders and widespread expression of immune-
checkpoint ligands [45, 46]. Many studies showed a positive 
correlation between the intestinal subtype and the microsat-
ellite unstable phenotype, whereas poorly cohesive and dif-
fuse histology are rarely associated with this GC subgroup. 
These findings are not always statistically robust, probably 
due to the small sample sizes involved in these studies [41, 
44, 45]. Moreover, in some reports, an association between 
MSI-H and tumour phenotype was not found [45, 46]. In 
clinical setting, patients with MSI-H GC show a significant 
longer overall survival (OS) compared with those who have 
GC with MSS GC features. It has been argued that MSI-H 
GC has a better prognosis due to its correlation with earlier 
TNM stage at diagnosis (stages I–II), limited lymph-node 
metastasis, and Lauren intestinal histotype [45, 46]. Moreo-
ver, immunological assessment of the microenvironment in 
MMRD tumours exhibits enhanced attraction of tumour-
infiltrating lymphocytes and widespread expression of sev-
eral immune checkpoint ligands like PD-L1, LAG-3, IDO, 
and CTLA4 [52, 53]. The higher mutational rate of MSI-H 
tumours compared with MSS group may explain these find-
ings [21–23]. Tumours with high mutational burden have 
the potential to encode non-self immunogenic neoepitopes, 
which, in turn, activate recruitment of lymphocytes within 
the tumour, thus inducing an intense immune response [23, 
52]. At the same time, the active immune microenvironment 
is counterbalanced by the expression of immune inhibitory 
signals that contrast tumour elimination, as illustrated in 
Fig. 1 [21, 22, 52, 54]. The hyper-activation of cytotoxic 
lymphocytes within the tumour may lead to increased apop-
tosis of neoplastic cells, explaining the better outcomes of 
MSI-H GC patients compared to the MSS subgroup [20]. 
The Medical Research Council Adjuvant Gastric Infusional 
Chemotherapy (MAGIC) trial is the first prospective study 
reporting an association among MSI-H, MMRD, clinical 
features, and survival in patients with non-metastatic GC 
[20, 56]. This phase III study compared the effect of periop-
erative chemotherapy with epirubicin, cisplatin, and 5-fluo-
rouracil plus surgery with surgery alone, in patients with 
resectable gastroesophageal cancer. Considering the clinico-
pathological features of patients included in the trial, female 
sex, older median age, Lauren intestinal subtype, low rate of 
metastatic lymph nodes, and stomach location were found to 
be correlated to the MSI-H subgroup (8.5% of all patients), 
compared with MSS and MSI-L classes [20]. Although none 
of the reported differences between MSI-H and MSS-L cases 
resulted significant, data from MAGIC trial are widely over-
lapping and confirm the main retrospective reports concern-
ing microsatellite unstable GC [20, 42, 45, 46].
MSI survival and response to chemotherapy 
in the early and advanced stages of GC
The positive association between MSI-H phenotype, 
MMRD, and better prognosis has been suggested in several 
GC studies [41, 45, 46]. Two recent meta-analyses includ-
ing 17 and 21 studies, respectively, found a consistent posi-
tive effect of microsatellite unstable status on prognosis [42, 
45]. Interestingly, the four different TCGA subgroups of GC 
[5] have been correlated to survival outcomes in another 
study [57]. In particular, the EBV subtype reported the best 
prognosis and the genomic stable (GS) subtype the worst. 
Microsatellite unstable subgroup and CIN are related with 
poor OS compared to EBV subtype but with more favourable 
survival rates compared with GS patients. These results were 
mainly attributable to the inflammatory microenvironment 
and immune response observed in subtypes with a better 
prognosis. More precisely, the immune response resulted 
strongly enhanced due to viral infection in EBV subtype and 
as a consequence of higher mutational rate in microsatel-
lite unstable group. These events might prevent outgrowth 
of cancer cells and promote their apoptosis, resulting in 
improved OS [57]. In agreement with these results, a posi-
tive effect of microsatellite stable vs unstable status on sur-
vival, but restricted only to stage II disease, has been found 
in a retrospective trial involving 510 operated chemo-radio 
naïve GC, with 16% of MSI-H patients [58]. The recent post 
hoc analysis of the MAGIC trial first established a correla-
tion between microsatellite status and survival in a rand-
omized prospective study with a control group, confirming 
the positive prognostic value of MSI-H in GC chemo-radio 
naïve population [20]. Considering the group treated with 
surgery, OS was significantly better for patients with MSI-H 
than for those with MSS or MSI-L [20]. Moreover, MSI-H 
counteracts the negative impact of positive resection margin 
(R+) after gastrectomy on prognosis, as reported in a recent 
large retrospective study [59]. In this study, gastric cancer 
patients were stratified in MSI-H (26.4% of patients) and 
MSS (73.6% of patients) groups. Despite the presence of R+ 
margin status, long term-survival outcomes were reported 
in the MSI-H group only, with higher 3-, 5-, and 10-year 
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disease-specific survival rates compared to MSS patients 
[59]. A large amount of studies attempted to define the 
prognostic value of MSI-H, but far less data regarding this 
molecular feature and response to chemotherapy are avail-
able. Retrospective Asian studies supported the hypothesis 
that MSI-H stage II and III GC patients do not gain any 
benefit from adjuvant 5-fluorouracil-based chemotherapy, 
whereas patients with MSS do [18, 19, 43]. This was verified 
also in the MAGIC trial where MSI-H patients treated with 
perioperative chemotherapy reported a twofold higher risk of 
death compared with those with MSS [20]. Recently, a pro-
spective genomic-profiling research confirmed the MAGIC 
trial results and extended the predictive meaning of MSI also 
to the metastatic setting [60]. Metastatic oesophageal and 
GC samples were evaluated and 3% of patients were scored 
MSI-H. MSI-H tumours showed rapid disease progression 
on standard cytotoxic therapy with a significantly shorter 
progression-free survival compared with MSS patients 
[60]. The fast-progressing patients received the following 
line of treatment with anti-PD-1 antibodies (durvalumab, 
pembrolizumab, and nivolumab), as a single therapy or 
in combination with anti-CTLA4 antibodies (ipilimumab, 
tremelimumab). Nearly half of the patients with durable 
immunotherapy responses showed a higher mutational rate 
and an MSI-H status [60]. The detrimental effect of chemo-
therapy compared with the remarkable results reported in 
immunotherapeutic trials may be explained on the basis of 
the peculiar behaviour and molecular features of MSI-H 
tumours reported above [5, 21–23, 52]. The MAGIC trial 
authors focused their attention on the unexpected differ-
ent outcomes between MSI-H GC and colon cancer out-
comes towards chemotherapy [20]. The choice of different 
platinum compound administered in the MAGIC trial—
cisplatin for GC—and in colorectal cancer adjuvant stud-
ies—oxaliplatin—may have influenced the results [20, 61]. 
In fact, in preclinical studies, hMLH1-deficient colon and 
endometrial cell lines have been reported to be resistant 
to cisplatin, but not to oxaliplatin [61]. Another interest-
ing hypothesis suggested by MAGIC trial reports is based 
on the immune tumour microenvironment: MSI-H tumours 
are strongly associated with a vigorous immune infiltrate 
[20–23, 52], which may suppress the residual micrometas-
tases after surgery [20]. Chemotherapy administration may 
have a negative effect on the immune defences, reducing 
the innate positive effect of the MSI-H phenotype on prog-
nosis, whereas immune-checkpoint inhibitors may have a 
synergistic activity with immune response. Despite lacking 
of a strong validation [17–19, 42, 45], all these data suggest 
the future possibility of sparing unnecessary or even worse 
detrimental chemotherapy to MSI-H GC patients, basing the 
chemotherapeutic decision-making on molecular level for 
each patient selection [20]. The opportunity of alternative 
therapeutic strategies for this GC subtype, especially focused 
on the immune response, might be a step towards a more 
personalized treatment and central issue for future studies.
Correlation among MSI, immune response, 
and checkpoint inhibitors: clinical 
implications
Targeting immune checkpoints with monoclonal antibod-
ies has recently reached exciting goals and it represents a 
promising strategy for treatment of several tumours [21, 
22, 62]. Among gastrointestinal cancers, the first evidences 
of correlation between microsatellite unstable status and 
PD-L1 expression were established in colorectal tumours 
[33, 52, 53]. The immune microenvironment in primary 
colorectal cancer samples from MSI-H tumours presents 
a high T-helper 1/cytotoxic lymphocytes infiltrate and a 
widespread expression of the main immune-checkpoint 
molecules [52, 54]. These latter are negative regulators of 
T cell immune function; their inhibition results in increased 
activation of the immune response against tumour [52]. All 
compartments of MSI-H cancers, including tumour-infiltrat-
ing lymphocytes (TIL), stroma, and invasive front express 
many of these molecules, e.g., CTLA4, PD-1, PD-L1, LAG-
3, and IDO [52, 53]. In contrast, MSS tumours and their TIL 
show very little amount of immune checkpoints [5, 23, 52, 
54]. Based on these preliminary observations, in a phase 
II prospective clinical trial, a group of treatment-refractory 
metastatic patients with MMRD colorectal cancer, MMR-
proficient colon cancer, or MMRD non-colorectal cancer 
received pembrolizumab, an anti-PD-1 antibody [22]. MSI 
was found to be a significant predictor of overall response 
rate (ORR)—40% of ORR in MMRD colorectal cancer, 71% 
in MMRD non-colorectal cancer, 0% in MMR-proficient 
colorectal cancer and progression-free survival rate (78%, 
67%, and 11% in each subgroup, respectively) [22]. Mem-
branous PD-L1 positivity occurred only in MMRD cancers, 
prominently expressed on TIL and tumour-associated mac-
rophages located at the invasive fronts of the tumour [21, 
22]. The KEYNOTE-012 trial was designed to evaluate the 
efficacy of pembrolizumab in PD-L1 positive advanced gas-
tric adenocarcinomas [24]. 22% of patients with PD-L1-pos-
itive tumour showed a partial response. Genomic profiling 
revealed an MSI-H status in 17% of all patients; among 
patients with MSI-H GC, 50% reached partial response [24]. 
Moreover, MSI-H tumours exhibited responses to immune 
checkpoint inhibitors, regardless of PD-L1 expression [24, 
63, 64]. Results of these studies provided justification for 
focusing on microsatellite instability status as additional pre-
dictive biomarker of response to immunotherapy [64–66]. 
Pembrolizumab has been approved in 2017 by FDA for 
pre-treated metastatic GC patients with PD-L1-expressing 
tumours [66]. The drug registration is based on the results of 
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KEYNOTE 059 trial, testing pembrolizumab on 259 patients 
with gastric or gastroesophageal junction advanced adeno-
carcinoma [67]. Among these patients, 143 (55%) expressed 
PD-L1. Objective responses occurred in 13.3% of patients, 
with response duration ranged from 2.8 to 19.4 months 
[67]. Considering the MSI-H group, objective responses 
were even more impressive, with a reported ORR of 57% 
[67]. The response duration ranged from 5.3 to 14.1 months 
[67]. The CHECKMATE 032 study assessed the efficacy 
of nivolumab, another anti-PD-1 monoclonal IgG4 anti-
body, in a PD-L1 unselected metastatic GC population [65]. 
Response rate of 12% with a median duration of response 
of 7.1 months in responders was reported. Response rates 
in PD-L1 positive and negative patients resulted in 18% and 
12%, respectively [65]. The combination of nivolumab with 
ipilimumab, an anti-CTLA4 antibody, has been tested in the 
same setting in separate arms of the CHECKMATE 032 
study, with incremental benefits in terms of response for 
PD-L1 positive vs PD-L1 negative patients [65]. An explora-
tory analysis of the CHECKMATE 032 evaluated response 
rates and OS in nivolumab arm stratifying the patients by 
microsatellite status [61]. Molecular profiling revealed that 
28% were MSI-H. ORR was 29% in MSI-H patients, 11% in 
MSI-L or MSS patients, and 9% in patients with unknown 
microsatellite status [64]. 71%, 28%, and 26% of disease 
control rate were reported, respectively. MSI-H patients 
reached longer median OS (14.75 months) compared with 
the other subgroups [64]. Correlation between response rates 
and MMRD/MSI-H status leads to the approval of pem-
brolizumab for all pre-treated metastatic MSI-H tumours, 
regardless of primitive tumour site [55]. Probably, due to the 
smaller sample sizes of the studies, efficacy results of check-
point inhibitors in MSI-H GC are not as exciting as those 
reported in colon cancer trials [21, 22, 24, 63–67]. However, 
this therapeutic strategy is based on precise histo-patholog-
ical findings and strong molecular rationale [21–23], which 
support administration of checkpoint inhibitors in this GC 
subgroup in many settings of the disease.
Conclusions
Gastric cancer is one of the most aggressive malignancies, 
with high metastatic potential. Despite the strong efforts to 
define better curative strategies, chemotherapy and targeted 
drug administration did not provide the expected results 
and prognosis remains poor [1]. Many GC studies are now 
based on the evidence that patients’ survival and treatment 
response do not only depend on tumour staging but also on 
the heterogeneous molecular features of this malignancy [5, 
6, 20]. TCGA first provided a systematic classification of 
GC, focusing on genetic profiling, defining four different 
subtypes with specific molecular make-up [5]. Microsatellite 
unstable GC represents a group of particular interest since 
its peculiar immunological microenvironment and response 
to treatment [5, 23, 52, 53]. Large meta-analyses of ret-
rospective studies [42, 45, 46] and the MAGIC trial [20, 
56] allowed to consider MSI-H GC as a separate disease, 
mainly associated with older age, female sex, distal stomach 
location, multiple gastric cancer locations, and histologic 
intestinal type [20, 42, 45, 46]. These studies allowed alto-
gether identifying a prognostic and predictive meaning to 
this molecular subgroup, as already assessed in colorectal 
cancer [12, 15]. Even though MSI-H resulted associated 
with a better OS in chemo-naïve GC patients compared with 
MSS group [20], it was related to a higher risk of death 
and poorer outcomes when perioperative chemotherapy was 
administered in more advanced disease [20]. The exhaus-
tive molecular data of Memorial Sloan Kettering Cancer 
Centre, consistent with MAGIC results, extend the predic-
tive meaning of microsatellite status to the metastatic set-
ting and support the administration of checkpoint inhibi-
tors to heavily pre-treated MSI-H GC patients [60]. Hence, 
the detrimental effects of chemotherapy compared with the 
promising results obtained with immune-checkpoint inhibi-
tors have been explained on the basis of the peculiar immune 
microenvironment described in MSI-H tumours. In conclu-
sion, MSI-H GC shows typical histological and molecular 
features, defined clinical behaviour, and peculiar responses 
to treatments [6, 20–22, 24, 64]. These evidences suggest 
that it might be useful to test GC patients for microsatel-
lite status in all the stages of disease. Further prospective 
studies, especially for the early stages, with a pre-planned 
genetic profiling of GC patients, might validate the cur-
rent evidences. Despite the encouraging results, a substan-
tial portion of MSI-H GC patients do not gain any benefit 
even from immunotherapy [21, 22, 24, 64]. Hence, tailored 
immunotherapeutic trials might be helpful to understand the 
interaction between immune microenvironment and molecu-
lar tumour profile, to eventually guarantee the most suitable 
treatment to every GC patient.
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